Search ↗
Tools / Calculator · FDA labeling criteria

Does your BMI meet
the label criteria?

Wegovy and Zepbound are approved for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. This calculates your BMI and checks it against those criteria. Meeting them is where a prescriber starts, not where they finish.

Weight-related conditions diagnosed

BODY MASS INDEX

— —
Weight for BMI 30 at your height—
Weight for BMI 27 at your height—

How it’s calculated

BMI = weight (kg) ÷ height (m)² Label criteria (Wegovy, Zepbound): BMI ≥ 30, or BMI ≥ 27 with ≥ 1 weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

Assumptions and limits

  • BMI does not distinguish muscle from fat; a muscular person can have a high BMI and low body fat. Use the body-fat calculator alongside it.
  • Meeting label criteria is a prescriber’s starting point. Contraindications (personal or family history of medullary thyroid carcinoma, MEN2, pregnancy) override it.
  • Compounded GLP-1 availability depends on FDA shortage status and state rules and is not covered by these criteria.
Read this first This tool does arithmetic on numbers you enter. It is not a diagnosis, a prescription or a treatment recommendation. Take the result to a licensed clinician.

References

Regulatory and primary sources

  1. DailyMed: Wegovy (semaglutide) labeling ↗ · indications and limitations of use
  2. DailyMed: Zepbound (tirzepatide) labeling ↗ · indications and limitations of use

Published literature

  1. Pedersen SD, Manjoo P, Dash S, et al.. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update.CMAJ 2025.PubMed 40789597 · doi:10.1503/cmaj.250502
  2. Misra A. Ethnic-Specific Criteria for Classification of Body Mass Index: A Perspective for Asian Indians and American Diabetes Association Position Statement.Diabetes Technol Ther 2015.PubMed 25902357 · doi:10.1089/dia.2015.0007

Literature retrieved from PubMed on October 18, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Related tools.

Read next.